![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1463640
Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : ¿¹Ãø(-2030³â) Áö¿ª ºÐ¼® - Á¦Ç°º°, ¼ö¼úº°, ÃÖÁ¾ »ç¿ëÀÚº°South & Central America Aortic Valve Replacement Devices Market Forecast to 2030 - Regional Analysis - by Product, Surgery, and End User |
Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº 2022³â 3¾ï 6,563¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 8¾ï 7,641¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.5%·Î ÃßÁ¤µË´Ï´Ù.
´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±âÀÇ Áøº¸°¡ Áß³²¹Ì ´ëµ¿¸Æ ÆÇ¸· ±³Ã¼ ÀåÄ¡ ½ÃÀåÀ» µÞ¹Þħ
°æ Ä«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)°ú °°Àº Àúħ½À ¼ö¼ú ÀýÂ÷(MIS)ÀÇ °³¹ßÀº ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ(AS)ÀÇ Ä¡·á¸¦ Çö´ëÈÇß½À´Ï´Ù. °æ Ä«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀº Á¾·¡ÀÇ °³½É¼úº¸´Ù ħ½ÀÀÌ Àû±â ¶§¹®¿¡ Áö±Ý±îÁö ¼ö¼úÀÇ ´ë»óÀÌ µÇÁö ¾Ê¾Ò´ø °íÀ§ÇèÀÇ È¯ÀÚ¿¡¼µµ Ä¡·á¸¦ ¹Þ°Ô µÇ¾ú½À´Ï´Ù. °Ô´Ù°¡, Àç·á¿Í µðÀÚÀÎÀÇ °³¹ßÀº ´õ ưưÇÏ°í »ýüÀûÇÕ¼ºÀÌ ³ôÀº ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀ» °³¹ßÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÇÕº´ÁõÀÇ À§ÇèÀ» °¨¼Ò½Ãŵ´Ï´Ù.
´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±âÀÇ ±â¾÷¿¡ ÀÇÇÑ ¸î °¡Áö ±â¼úÀû Áøº¸´Â ´ÙÀ½°ú °°½À´Ï´Ù.
2023³â 1¿ù, AbbottÀº °³½É¼ú À§ÇèÀÌ ³ôÀº ½É°¢ÇÑ ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ ȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇÑ °æ Ä«Å×ÅÍ ´ëµ¿¸Æ ÆÇ¸· À¯Ä¡(TAVI) ½Ã½ºÅÛ '³ªºñÅç'ÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. NavitolÀº AbbottÀÇ ±¤¹üÀ§ÇÑ °æ°æ Ä«Å×ÅÍ ±¸Á¶ ½ÉÀå Æ÷Æ®Æú¸®¿À¿¡ Âü°¡ÇÑ ÃֽŠÁ¦Ç°À¸·Î ÀÇ»ç¿Í ȯÀÚ¿¡°Ô ´Ù¾çÇÑ ½É°¢ÇÑ ½ÉÀå Áúȯ¿¡ ´ëÇÑ Ä§½ÀÀÌ ÀûÀº Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.
2021³â 9¿ù, AbbotÀº ´ëµ¿¸Æ ÆÇ¸·°ú ½Â¸ðÆÇ Áúȯ ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀ» °³¼±Çϱâ À§ÇØ Epic Plus ¹× Epic Plus Supra Stented Tissue ValvesÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ »õ·Î¿î Àåºñ·Î ¾Öº¿Àº ¿¡ÇÈ ¼ö¼ú ¹ëºê Ç÷§ÆûÀ» È®ÀåÇß½À´Ï´Ù.
µû¶ó¼ ±â¼úÀû Áøº¸´Â ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ ¸¸µé¾î ³Â½À´Ï´Ù.
Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå °³¿ä
Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõÀÇ À¯º´·ü ±ÞÁõ, ÆÇ¸· ´ëü ¼ö¼ú¿¡ ´ëÇÑ ÀÎÁöµµ¸¦ ³ôÀ̱â À§ÇÑ ´Ù¾çÇÑ Á¤ºÎ Á¶Á÷ÀÇ ³ë·Â¿¡ ÀÇÇØ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.
Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(±Ý¾×)
Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼¼ºÐÈ
Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº Á¦Ç°, ¼ö¼ú, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
Á¦Ç°º°·Î Áß³²¹Ì ´ëµ¿¸Æ ¹ëºê ´ëü ÀåÄ¡ ½ÃÀåÀº ºÀÇÕµÇÁö ¾ÊÀº ¹ëºê¿Í ±â°è½Ä ¹ëºê·Î ºÐÇҵ˴ϴÙ. 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ ±³Ã¼ ÀåÄ¡ ½ÃÀåÀº ¹«ºÀÇÕ ¹ëºê°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¼ö¼ú¿¡ µû¶ó Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ³·Àº ħ½À ¼ö¼ú°ú °³º¹ ¼ö¼ú·Î ³ª´¹´Ï´Ù. ³·Àº ħ½À ¼ö¼ú ºÎ¹®Àº 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼ ´õ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå Á¡À¯À²¿¡¼ Ãִ븦 Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î Áß³²¹Ì ´ëµ¿¸ÆÆÇ ±³Ã¼ ÀåÄ¡ ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ºÐ·ùµË´Ï´Ù. ºê¶óÁúÀº 2022³â Áß³²¹Ì ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd, Artivion Inc, Venus MedTech HangZhou Inc, Labcor Laboratorios Ltda. µîÀÌ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.
The South & Central America aortic valve replacement devices market is expected to grow from US$ 365.63 million in 2022 to US$ 876.41 million by 2030. It is estimated to grow at a CAGR of 11.5% from 2022 to 2030.
Advancements in Aortic Valve Replacement Devices Fuels South & Central America Aortic Valve Replacement Devices Market
The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.
A few technological advancements by the players in the aortic valve replacement devices are mentioned below:
In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.
In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.
South & Central America Aortic Valve Replacement Devices Market Overview
The South & Central America aortic valve replacement devices market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the surge in prevalence of aortic stenosis, initiatives undertaken by various government organizations to create awareness about valve replacement surgeries.
South & Central America Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Aortic Valve Replacement Devices Market Segmentation
The South & Central America aortic valve replacement devices market is segmented into product, surgery, end user, and country.
Based on product, the South & Central America aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger South & Central America aortic valve replacement devices market share in 2022.
Based on surgery, the South & Central America aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger South & Central America aortic valve replacement devices market share in 2022.
Based on end user, the South & Central America aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest South & Central America aortic valve replacement devices market share in 2022.
Based on country, the South & Central America aortic valve replacement devices market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America aortic valve replacement devices market share in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd, Artivion Inc, Venus MedTech HangZhou Inc, and Labcor Laboratorios Ltda. , are some of the leading companies operating in the aortic valve replacement devices market.